Abstract
Background and aims: E1B-deleted virus dl1520 (ONYX-015) has been previously used in clinical trials mainly for treatment of head and neck tumors, and has been shown to have beneficial effects independent of p53 status. The main aim of this investigation was to carry out a preclinical study for assessment of the use of dl1520 in in vitro and in vivo hepatocellular carcinoma (HCC) models with various p53 status (deleted, mutant, and wild type), and study the ultrastructural changes in the carcinoma cells during and following treatment with dl1520. Methods: dl1520 (ONYX-015) virus was used for treatment of three HCC cell lines in culture, then for treatment of developed xenografts in SCID mice. The effects of dl1520 on HCC cell growth and accompanied morphological changes were assessed by various techniques including transmission electron microscopy. dl1520 infection was confirmed using polymerase chain reaction and immunolabeling at transmission electron microscopy level. Results: dl1520 was effective in killing cells and inhibiting HCC cell growth both in vitro and in vivo. The cell killing was at higher levels in cells possessing abnormal p53. Survival rates in SCID mice treated with dl1520 were statistically significantly higher in HCC tumors with deleted and mutant p53, than in tumors with wild-type p53. Conclusions: The findings in this study suggest that dl1520 could be safely and effectively used for treatment of HCC dependent on the p53 status of the cells in vivo. Characteristic morphological changes that took place in the dl1520-treated HCC cells/tumors were distinct at transmission electron microscopy level and are the first of their kind to be reported.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Lotze MT, Flickinger JC, Carr B . In Hepatobiliar neoplasms Anonymous Cancer: Principles and Practice of Oncology Philadelphia, PA: Lippincott 1993 883–914
Fong Y, Blumgart LH . Hepatic colorectal metastases: current status of surgical therapy Oncology 1998 12: 1489–1498
Sherlock S, Dooley J . Diseases of the Liver and Biliary System Oxford, UK: Blackwell Scientific 1993
Nagashima I, Hamada C, Naruse K . Surgical resection for small hepatocellular carcinoma Surgery 1996 119: 40–45
Barker DD, Berk AJ . Adenovirus proteins from both E1B reading frames are required for the transformation of rodent cells by viral infection and DNA transfection Virology 1987 156: 107–121
Bischoff JR . An adenovirus mutant that replicates selectively in p53-deficient human tumour cells Science 1996 274: 373–376
Rothmann T, Hengstermann A, Whitaker NJ et al. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumour cells J Virol 1998 72: 9470–9478
Goodrum FD, Ornelles DA . p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection J Virol 1998 72: 9479–9490
Hay JG, Shapiro N, Sauthoff H et al. Targeting the replication of adenoviral gene therapy vectors to lung cancer cells: the importance of the adenoviral E1b-55kD gene Hum Gene Ther 1999 10: 579–590
Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn D . ONYX-015, an E1B gene-attenuated adenovirus, causes tumour-specific cytolysis and antitumoural efficacy that can be augmented by standard chemotherapeutic agents Nat Med 1997 3: 639–644
Harada JN, Berk AJ . p53-independent and -dependent requirements for E1B-55K in adenovirus type 5 replication J Virol 1999 72: 5333–5344
Vollmer CM, Ribas A, Butterfield LH et al. p53 selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma Cancer Res 1999 59: 4369–4374
Kirn D, Hermiston T, McCormick F . ONYX-015: clinical data are encouraging Nat Med 1998 4: 1341–1342
Ganly I, Kirn D, Eckhardt G et al. A phase I study of Onyx-015, an E1B attenuated adenovirus administered intratumorally to patients with recurrent head and neck cancer Clin Cancer Res 2000 6: 798–806
Heise C, Williams A, Xue S et al. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy Cancer Res 1999 59: 2623–2628
Habib NA, Sarraf CE, Mitry RR et al. E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumours Hum Gene Ther 2001 12: 219–226
Reid T, Galanis E, Abbruzzese J et al. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial Gene Ther 2001 8: 1618–1626
Lane DP . Killing tumour cells with viruses — a question of specificity Nat Med 1998 4: 1012–1013
Lowe SW . Progress of the smart bomb cancer virus Nat Med 1997 4: 1012–1013
Sambrook J, Fritsch EF, Maniatis T . Molecular Cloning: A Laboratory Manual New York: Cold Spring Harbour Laboratory 1989
Mitry RR, Sarraf CE, Havlik R et al. Detection of adenovirus and initiation of apoptosis in hepatocellular carcinoma cells after Ad-p53 treatment Hepatology 2000 885–889
Yang CT, You L, Uematsu K, Yeh CC, McCormick F, Jablons DM . p14(ARF) modulates the cytolytic effect of ONYX-015 in mesothelioma cells with wild-type p53 Cancer Res 2001 61: 5959–5963
Wyllie AH . Cell death is a new classification separating apoptosis from necrosis In: Browen ID, Lockshin RA, eds Cell Death in Biology and Pathology New York: Chapman & Hall 1981 9–29
Alison MR, Sarraf CE . Apoptosis as a gene-directed program of cell death In: Bittar ED, Bittar N, eds Principles of Medical Biology Stamford, CT: JAI Press 1998 1–55
Greber UF, Willetts M, Webster P . Stepwise dismantling of adenovirus 2 during entry into cells Cell 1993 75: 477–486
Acknowledgements
We thank Professor Arnold Berk, University of Southern California, Los Angeles, for kindly providing the dl1520 adenovirus, the Pedersen Family Charitable Foundation for vital financial support, and VE Emons, Department of Histopathology, Imperial College School of Medicine, for preparing tissues for electron microscopy.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Habib, N., Mitry, R., Sarraf, C. et al. Assessment of growth inhibition and morphological changes in in vitro and in vivo hepatocellular carcinoma models post treatment with dl1520 adenovirus. Cancer Gene Ther 9, 414–420 (2002). https://doi.org/10.1038/sj.cgt.7700455
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7700455
Keywords
This article is cited by
-
The biology of Hepatocellular carcinoma: implications for genomic and immune therapies
Molecular Cancer (2017)
-
Dual induction of PKR with E2F-1 and IFN-α to enhance gene therapy against hepatocellular carcinoma
Cancer Gene Therapy (2008)
-
Oncolytic viral therapies
Cancer Gene Therapy (2004)
-
Selectively replicating viral vectors
Cancer Gene Therapy (2002)